Anti-Amyloid

In cell studies huperzine A shifts amyloid precursor protein processing away from the amyloidogenic route, down-regulating BACE1 and up-regulating ADAM10, the β- and α-secretase steps that decide whether APP becomes amyloid-β ^{4,5Reference 4Qian ZM · 2014ReviewHuperzine A: is it an effective disease-modifying drug for Alzheimer’s disease? — reviewView study →Reference 5Wongjaikam S et al. · 2024In vitroHuperzine A regulates the physiological homeostasis of amyloid precursor protein proteolysis and tau protein conformation — in vitro / in silicoView study →}, and reduces amyloid-β-induced oxidative injury ^{4Reference 4Qian ZM · 2014ReviewHuperzine A: is it an effective disease-modifying drug for Alzheimer’s disease? — reviewView study →}. Naming both enzymes makes it a specific claim at the branch point rather than a generic reduction in plaques.

All of it is cell and animal work. The human trials measure cognition rather than amyloid, and the best-designed of them, the US ADCS phase II RCT (n=210), was negative on its primary cognitive endpoint ^{6Reference 6Rafii MS et al. · 2011RCTA phase II trial of huperzine A in mild to moderate Alzheimer disease — randomised controlled trialView study →}.

Water extract improved memory and executive function in β-amyloid-overexpressing (5xFAD and Tg2576) mice, attenuated hippocampal mitochondrial dysfunction, reduced oxidative stress and activated NRF2-regulated antioxidant genes ^{7,8Reference 7Matthews et al. · 2019AnimalCentella asiatica improves memory and promotes antioxidative NRF2 signaling in 5XFAD mice — animal modelView study →Reference 8Gray et al. · 2018AnimalCentella asiatica attenuates hippocampal mitochondrial dysfunction and improves memory and executive function in β-amyloid overexpressing mice — animal modelView study →}.

The studies do not report plaque burden or secretase activity, so the mechanism is indirect: the herb protects neurons in an amyloid-loaded brain rather than interfering with amyloid production or clearance, which predicts symptom protection rather than disease modification.

Everything is preclinical, and human pharmacokinetics show the parent glycosides are poorly absorbed ^{9,10Reference 9Songvut et al. · 2019Clinical trialSafety and pharmacokinetics of standardized extract of Centella asiatica (ECa 233) capsules in healthy volunteers — phase 1 clinical trialView study →Reference 10Songvut et al. · 2021Clinical trialPharmacokinetics and metabolomics of an orally modified formula of standardized Centella asiatica extract in healthy volunteers — clinical trialView study →}, so the doses producing these effects in mice may not be reachable in people.

In a β-amyloid (Aβ1-42) mouse Alzheimer’s model, 14 days of oral POEE prevented cognitive impairment while reducing amyloid deposits, astrogliosis and CA1 hippocampal neuron loss ^{11Reference 11Figueiró et al. · 2011AnimalThe Amazonian herbal Marapuama attenuates cognitive impairment and neuroglial degeneration in a mouse Alzheimer model — animal studyView study →}, three pathological endpoints moving together with the functional one.

No secretase step is identified, so whether the extract reduces amyloid production, increases clearance or protects neurons well enough that less pathology accumulates is unresolved.

It is one study, in mice, with no human data and no identified active constituent, and fourteen days is short for an amyloid endpoint.